Inflammatory Breast Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Conditions: Breast Inflammatory Carcinoma; Recurrent Breast Inflammatory Carcinoma; Stage IV Breast Inflammatory Carcinoma Interventions: Drug: Eribulin Mesylate; Drug: Grapiprant Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 10, 2021 Category: Research Source Type: clinical trials
